Get started
Author

Aurélie De Bruycker

Observed names: A. De Bruycker, A. de Bruycker, Aurélie de Bruycker
ORCID: 0000-0002-3583-481X
Observed ORCID: 0000-0002-3583-481X
OpenAlex ID: A5031146596
Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial
2017 · Piet Ost, Dries Reynders, et al. · Journal of Clinical Oncology · 1,354
Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials
2022 · Matthew P. Deek, Kim Van der Eecken, et al. · Journal of Clinical Oncology · 264
PDF
Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial.
2020 · Piet Ost, Dries Reynders, et al. · Journal of Clinical Oncology · 156
Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study
2018 · T. Steuber, C. Jilg, et al. · European Urology Focus · 109
PEACE V – Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial
2020 · A. De Bruycker, A. Spiessens, et al. · BMC Cancer · 82
PDF
Prevalence and prognosis of low‐volume, oligorecurrent, hormone‐sensitive prostate cancer amenable to lesion ablative therapy
2017 · Aurélie De Bruycker, Bieke Lambert, et al. · British Journal of Urology · 63
Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment Templates
2018 · Aurélie De Bruycker, Elise De Bleser, et al. · European Urology · 59
Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time
2018 · Bert Dhondt, Elise De Bleser, et al. · World Journal of Urology · 36
Clinical perspectives from ongoing trials in oligometastatic or oligorecurrent prostate cancer: an analysis of clinical trials registries
2020 · Aurélie De Bruycker, Phuoc T. Tran, et al. · World Journal of Urology · 21
PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
2025 · Jack Andrews, Yohan Kim, et al. · Clinical Cancer Research · 20
PDF
A Trial-Based Cost-Utility Analysis of Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer
2020 · Elise De Bleser, Ruben Willems, et al. · Cancers · 14
PDF
Prospective Comparison of F-18 Choline PET/CT Scan Versus Axial MRI for Detecting Bone Metastasis in Biochemically Relapsed Prostate Cancer Patients
2017 · Wouter Huysse, Frédéric Lecouvet, et al. · Diagnostics · 13
PDF
Disease Control and Late Toxicity in Adaptive Dose Painting by Numbers Versus Nonadaptive Radiation Therapy for Head and Neck Cancer: A Randomized Controlled Phase 2 Trial
2024 · Aurélie De Bruycker, Wilfried De Neve, et al. · International Journal of Radiation Oncology*Biology*Physics · 12
PDF
Microbiome and metabolome dynamics during radiotherapy for prostate cancer
2023 · Willeke Danckaert, Mathieu Spaas, et al. · Radiotherapy and Oncology · 11
Breakdown walkout and its reduction in high-voltage pLDMOS transistors on thin epitaxial layer
1992 · M.-J. Zhou, A. de Bruycker, et al. · Electronics Letters · 11
Evaluation of chest CT-scans following lung stereotactic ablative radiotherapy: Challenges and new insights
2024 · Aurélie De Bruycker, Famke Schneiders, et al. · Lung Cancer · 9
Re: Gaëtan Devos, Gert De Meerleer, Steven Joniau. Have We Entered the Era of Imaging Before Salvage Treatment for Recurrent Prostate Cancer? Eur Urol 2019;76:265–7
2019 · Aurélie De Bruycker, Valérie Fonteyne, et al. · European Urology · 3
1251 Adaptive dose painting by numbers for head and neck cancer: long term analysis of a randomized trial.
2025 · Fréderic Duprez, Stéphanie Deheneffe, et al. · Radiotherapy and Oncology · 1
P-15 Implementation of cancer nurse-led consultations for patients with head and neck cancer through the care pathway: a renewed care
2021 · Annelies de Prins, Jaimie Saelens, et al. · Oral Oncology · 1
OC-0370: Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer (STOMP)
2020 · P. Ost, D. Reynders, et al. · Radiotherapy and Oncology · 1
SP-0375: Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence
2018 · P. Ost, D. Reynders, et al. · Radiotherapy and Oncology · 1
PDF
Supplementary Figure S4 from PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
2025 · Jack R. Andrews, Yohan Kim, et al.
Supplementary Figure S7 from PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
2025 · Jack R. Andrews, Yohan Kim, et al.
Supplementary Figure S9 from PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
2025 · Jack R. Andrews, Yohan Kim, et al.
Supplementary Figure S2 from PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
2025 · Jack R. Andrews, Yohan Kim, et al.
Works count: 37
Citation count: 2,241
H-index: 12
I10-index: 15
Year
Topic
Type